Financial Performance - The company achieved total revenue of CNY 2.25 billion in Q1 2023, representing a year-on-year increase of 9.09%[6] - Net profit attributable to shareholders reached CNY 630.35 million, up 26.22% compared to the same period last year[6] - The net profit excluding non-recurring items was CNY 617.64 million, reflecting a growth of 26.98% year-on-year[6] - Cash flow from operating activities surged to CNY 1.30 billion, a significant increase of 537.09% compared to the previous year[6] - The gross profit margin improved to 48.40%, an increase of 3.16 percentage points from the previous year, with gross profit amounting to CNY 1.09 billion[12] - Revenue from the small molecule CDMO business was CNY 2.00 billion, a year-on-year increase of 4.31%, with a 45.37% growth when excluding large orders[13] - Emerging business revenue reached CNY 249 million, marking a substantial growth of 72.54% year-on-year[14] - Total operating revenue for Q1 2023 reached ¥2,249,034,497.62, an increase of 9.1% compared to ¥2,061,708,856.14 in Q1 2022[24] - Operating profit for Q1 2023 was ¥709,948,636.92, up 24.5% from ¥570,097,662.75 in the same period last year[24] - Net profit attributable to shareholders for Q1 2023 was ¥630,346,004.43, compared to ¥499,398,084.81 in Q1 2022, reflecting a growth of 26.2%[25] - Basic and diluted earnings per share for Q1 2023 were both ¥1.72, an increase from ¥1.36 in Q1 2022[25] Assets and Liabilities - The total assets at the end of the reporting period were CNY 18.55 billion, a 1.69% increase from the end of the previous year[6] - Total current assets amount to ¥11,977,491,343.33, an increase from ¥11,860,458,372.35 at the beginning of the year[21] - Total liabilities decreased to ¥2,176,785,958.74 in Q1 2023 from ¥2,544,270,867.15 in Q1 2022, a reduction of approximately 14.5%[24] - Total equity attributable to shareholders increased to ¥16,324,854,569.41 in Q1 2023, up from ¥15,647,427,643.90 in Q1 2022, representing an increase of 4.3%[24] - The total liabilities and equity combined amounted to ¥18,546,760,048.14 in Q1 2023, compared to ¥18,239,273,651.93 in Q1 2022[24] Cash Flow - The cash inflow from operating activities for Q1 2023 was CNY 2,861,189,791.85, an increase of 48.8% compared to CNY 1,925,864,058.95 in Q1 2022[28] - The net cash flow from operating activities reached CNY 1,303,525,263.66, significantly up from CNY 204,607,061.83 in the same period last year[28] - Cash inflow from investment activities totaled CNY 8,399,828,818.08, compared to CNY 611,137,118.87 in Q1 2022, marking a substantial increase[28] - The net cash outflow from investment activities was CNY 327,218,213.85, an improvement from a net outflow of CNY 1,131,790,662.67 in Q1 2022[28] - The cash flow from financing activities showed a net inflow of CNY 383,841,586.32, with cash outflow for dividend payments recorded at CNY 3,889,772.50[29] - The total cash and cash equivalents at the end of Q1 2023 amounted to CNY 5,379,198,112.41, down from CNY 5,642,739,406.29 at the end of Q1 2022[29] - The company reported a cash inflow from the recovery of investments of CNY 8,368,856,153.32, a significant increase from CNY 607,807,000.00 in the previous year[28] - The cash outflow for purchasing goods and services was CNY 638,798,212.57, a decrease from CNY 1,003,677,026.11 in Q1 2022[28] - The total cash inflow from operating activities was CNY 2,861,189,791.85, while total cash outflow was CNY 1,557,664,528.19, resulting in a net cash flow of CNY 1,303,525,263.66[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 73,675[16] - ASYMCHEM LABORATORIES, INCORPORATED holds 31.12% of shares, totaling 115,133,168 shares[16] - HAO HONG holds 3.86% of shares, totaling 14,268,699 shares[16] - The company repurchased a total of 5,229,266 shares, accounting for 1.4134% of the total A+H share capital[18] - The company has not completed the transfer procedures for the employee stock ownership plan as of the end of the reporting period[19] Research and Development - Research and development expenses for Q1 2023 were ¥162,096,744.48, compared to ¥130,883,695.56 in Q1 2022, indicating a rise of 23.8%[24] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[23] Market Expansion - The company plans to expand its market presence in Europe and Japan while focusing on cost control and efficiency improvements[12]

证券代码：002821 证券简称：凯莱英 公告编号：2023-023 凯莱英医药集团（天津）股份有限公司 出席本次说明会的人员有：公司董事长、首席执行官HAO HONG，董事、首席 财务官张达，高级副总裁兼董事会秘书徐向科，独立董事王青松（具体参会人员 以实际出席为准）。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 20日（星期四）15：00前访问 https://ir.p5w.net/zj/，或扫描下方二维码， 进入问题征集专题页面。在信息披露允许的范围内，公司将在本次说明会上对投 资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）于2023年3月31 日 披 露 了 2022 年 年 度 报 告 全 文 及 摘 要 ， 相 关 内 容 详 见 巨 潮 资 讯 网 （http ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a year-over-year growth of 25%[8]. - The company's operating revenue for 2022 reached ¥10,255,325,392.82, representing a 121.08% increase compared to ¥4,638,834,177.53 in 2021[14]. - The net profit attributable to shareholders for 2022 was ¥3,301,635,019.64, a significant increase of 208.77% from ¥1,069,273,577.50 in the previous year[14]. - The basic earnings per share for 2022 was ¥9.02, an increase of 186.35% compared to ¥3.15 in 2021[14]. - The company has set a revenue guidance of 1.8 billion RMB for the next fiscal year, reflecting a growth target of 20%[8]. - The gross margin improved to 45%, up from 40% in the previous year, due to enhanced operational efficiencies[8]. - The company reported a total cash dividend of RMB 1,456,119,192.54, which includes RMB 656,437,642.20 in cash dividends and RMB 799,681,550.34 from other methods such as share repurchase[153]. Research and Development - The R&D investment for new products and technologies reached 200 million RMB, accounting for 13% of total revenue, indicating a strong focus on innovation[8]. - The number of new drug applications submitted to regulatory authorities increased by 30%, reflecting the company's commitment to innovation and development[7]. - The company aims to launch three new innovative drugs in the next fiscal year, with expected sales of over 500 million RMB[7]. - The company has established a world-class R&D platform with over 4,656 scientists and engineers, focusing on continuous production and enzyme engineering technologies, which are critical for maintaining its competitive edge in the CDMO industry[32]. - The company is focused on expanding its clinical research services and aims to enhance the synergy between clinical CRO services and CDMO services[106]. - The company is actively involved in the development of new pharmaceutical technologies and processes, leveraging over 20 years of experience in the industry[136]. Market Expansion and Strategy - The company plans to expand its market presence in Europe and North America, targeting a 15% increase in market share over the next three years[8]. - The company is targeting increased penetration in the Japanese market and aims to achieve greater breakthroughs in the European market through new technologies[102]. - The company aims to deepen relationships with large clients and expand its market presence in Europe and Japan while focusing on cost control and efficiency improvements in 2023[101]. - The company is committed to optimizing management methods to improve R&D efficiency and reduce production costs, with a focus on early project development[103]. - The company is exploring potential acquisitions to enhance its capabilities in biologics, with a budget of 300 million RMB allocated for this purpose[8]. Operational Efficiency - The company aims to reduce production costs and improve efficiency through continuous process optimization during the commercialization phase[25]. - The company has developed a comprehensive operational system that meets the highest global industry standards, ensuring efficient project management and quality control throughout the drug development lifecycle[33]. - The company has implemented a new operational strategy focused on sustainability, aiming to reduce production waste by 40% over the next three years[132]. - The company has established a competitive compensation system to attract and retain high-quality employees, which includes basic salary, performance bonuses, and other benefits[151]. Corporate Governance - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making or operational activities[112]. - The company has a clear performance evaluation and incentive mechanism to enhance work motivation and achieve operational goals[114]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[114]. - The company has established a performance evaluation system for senior management, linking compensation to the achievement of annual performance targets[158]. Environmental Compliance - Kailaiying Pharmaceutical Group strictly adheres to various environmental protection laws and regulations, ensuring compliance in its production operations[165]. - The company has established comprehensive waste treatment facilities, ensuring stable operation in accordance with national and local standards[166]. - The company has implemented new technologies to monitor and control emissions more effectively[175]. - The company has achieved compliance with national environmental standards, significantly reducing emissions of pollutants such as VOCs and COD[180]. Talent Development - The company has established the "Kailaiying Learning Center" to enhance employee training and development, focusing on cultivating elite talents in the CDMO sector[152]. - The company has a dual career development pathway for employees, allowing for both management and technical career advancements[152]. - The company emphasizes a people-oriented approach to human resource management, establishing mechanisms for talent selection, evaluation, and incentives to enhance sustainable development capabilities[108]. Risk Management - The company faces several risks, including the potential withdrawal or large-scale recall of major innovative drugs, operational risks in clinical projects, and risks related to the lifecycle replacement of key innovative drugs[2]. - The company has not reported any significant changes in the feasibility of its projects[92]. - The company did not identify any major risks or issues during its self-inspection of corporate governance and internal controls[164].

Financial Performance - The company's revenue for 2020 was CNY 3,149,689,675.80, representing a 28.04% increase from CNY 2,459,985,533.80 in 2019[14]. - The net profit attributable to shareholders for 2020 was CNY 722,091,360.68, a 30.37% increase compared to CNY 553,863,836.07 in 2019[14]. - The net profit after deducting non-recurring gains and losses was CNY 643,971,039.13, up 31.79% from CNY 488,626,334.69 in 2019[14]. - The company's total assets increased by 90.42% to CNY 7,157,565,543.71 at the end of 2020, compared to CNY 3,758,736,367.43 at the end of 2019[14]. - The basic earnings per share for 2020 was CNY 3.10, reflecting a 28.10% increase from CNY 2.42 in 2019[14]. - The diluted earnings per share for 2020 was CNY 3.08, an increase of 28.33% from CNY 2.40 in 2019[14]. - The net cash flow from operating activities for 2020 was CNY 569,291,589.49, a decrease of 5.26% from CNY 600,867,843.92 in 2019[14]. - The company reported a weighted average return on equity of 18.16% for 2020, down from 19.92% in 2019[14]. - The company received government subsidies amounting to CNY 99,257,315.07 in 2020, compared to CNY 90,483,570.77 in 2019[19]. - The company achieved total revenue of 3.15 billion yuan in 2020, a year-on-year increase of 28.04%, and a quarterly revenue of 1.067 billion yuan in Q4, marking a historical high with a growth of 48.69%[44]. Market Position and Strategy - As a leading global CDMO, the company focuses on technological innovation and commercialization in pharmaceutical processes, providing one-stop CMC services to large and medium-sized pharmaceutical and biotechnology companies[2]. - The company operates under a model that separates marketing authorization from production, allowing for flexibility in manufacturing partnerships[5]. - The company is involved in both clinical and commercial stages of drug development, focusing on innovative drugs and generic drugs[5]. - The company has served over 800 global clients and participated in more than 600 clinical projects, establishing itself as a long-term strategic partner for several multinational pharmaceutical companies[22]. - The company aims to leverage its technological innovations and platform advantages to continuously extend its service offerings and enhance competitive advantages in the CDMO sector[26]. - The company is strategically positioning itself to meet the growing demand in emerging markets, particularly in the Chinese biotechnology sector[43]. Research and Development - The company invested 259 million yuan in R&D, a 34.50% increase year-on-year, representing 8.22% of total revenue, with a total of 279 patent applications filed by the end of the reporting period[55]. - The company has filed a total of 279 patents and has been granted 159 patents, with 27 papers published in leading international journals[37]. - The application rate of continuous reaction technology and biocatalysis in the company's clinical late-stage projects exceeds 30%[31]. - The company has developed a biocatalysis platform with over 1,600 enzymes, including more than 800 proprietary enzymes, to enhance its enzyme-related service capabilities[64]. - The company established a Center of Excellence for Process Science (CEPS) to enhance R&D efficiency and address complex process challenges[58]. Risk Management - The company faces several risks, including the potential withdrawal or large-scale recall of major innovative drugs, operational risks in clinical projects, and risks related to international trade friction and exchange rate fluctuations[2]. - The company emphasizes the importance of risk awareness for investors regarding forward-looking statements and future plans[2]. Corporate Governance - The board of directors and management have confirmed their attendance and participation in the review of the annual report, ensuring governance and accountability[2]. - The company has established a comprehensive corporate governance structure and internal control system to ensure fairness and transparency for all shareholders[155]. - The company has maintained a stable management structure with no significant changes in board members during the reporting period[196]. Environmental Responsibility - The company has maintained compliance with environmental standards, with no instances of exceeding pollutant discharge limits reported[156]. - The company has achieved a VOCs emission concentration of 38.2 mg/m³ at the process exhaust outlet, with total emissions of 26.13 tons, equating to an annual emission of 52.27 tons[159]. - The company has been recognized as a national-level "green factory" by the Ministry of Industry and Information Technology, emphasizing its commitment to environmental protection and sustainable practices[159]. Shareholder Returns - The company proposed a cash dividend of RMB 6.00 per 10 shares for the 2020 fiscal year, which is subject to approval at the annual shareholders' meeting[122]. - The cash dividend for 2020 is fully funded from the company's distributable profits, which totaled RMB 183,406,819.45[124]. - The company has a structured plan for shareholder returns for the years 2020-2022, aligning with its financial strategy[124]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB[129]. - The company plans to continue focusing on the development of innovative drugs and enhancing its CDMO capabilities to capitalize on market growth opportunities[106]. - The company is exploring new product development and technological advancements to stay competitive in the market[199].

Financial Performance - The company's operating revenue for Q1 2020 was ¥475,496,806.78, a decrease of 0.21% compared to ¥476,494,446.55 in the same period last year[8] - Net profit attributable to shareholders increased by 17.34% to ¥108,029,889.53 from ¥92,063,799.35 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥93,342,503.90, up 16.33% from ¥80,239,049.36 in the previous year[8] - Basic and diluted earnings per share increased by 17.50% to ¥0.47 from ¥0.40 year-on-year[8] - The company reported a total comprehensive income of 110,265,879.79 CNY for the quarter, compared to 95,879,096.52 CNY in the previous year, indicating a growth of around 15%[41] - The total operating revenue for the first quarter was 119,349,601.73 CNY, an increase from 102,899,107.24 CNY in the previous year, representing a growth of approximately 15.5%[40] - The net profit for the first quarter reached 108,029,889.53 CNY, compared to 92,063,799.35 CNY in the same period last year, marking an increase of about 17.3%[40] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 34.93% to ¥49,207,245.92 compared to ¥75,617,344.15 in the same period last year[8] - Cash received from operating activities decreased by 77.18% to ¥1,362,572.64, attributed to a reduction in other receivables[16] - The company's cash and cash equivalents decreased to ¥380,914,652.63 from ¥435,252,214.16, indicating a decline in liquidity[30] - The cash inflow from operating activities amounted to ¥590,399,514.40, slightly up from ¥588,254,842.79 in the previous period[47] - The cash outflow from operating activities totaled ¥541,192,268.48, an increase from ¥512,637,498.64 year-over-year[48] - The cash and cash equivalents at the end of the period were ¥362,991,966.61, down from ¥598,029,313.74 in the previous period[49] - The net increase in cash and cash equivalents was -¥51,392,687.01, compared to -¥61,941,730.19 in the prior period[49] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,839,819,411.87, an increase of 2.16% from ¥3,758,736,367.43 at the end of the previous year[8] - Total liabilities amounted to CNY 682,523,881.63, down from CNY 713,232,174.09[32] - The company's retained earnings increased to CNY 1,805,596,685.22 from CNY 1,697,566,795.69[33] - The total liabilities for the first quarter of 2020 were CNY 721,803,350.68, with current liabilities at CNY 707,264,693.11 and non-current liabilities at CNY 14,538,657.57[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,404[12] - ASYMCHEM LABORATORIES, INCORPORATED held the largest share, with a holding ratio of 39.61% and 91,647,220 shares[12] - Net assets attributable to shareholders rose by 3.67% to ¥3,157,295,530.24 from ¥3,045,504,193.34 at the end of the previous year[8] - Owner's equity increased to CNY 3,157,295,530.24 from CNY 3,045,504,193.34[33] Research and Development - Research and development expenses increased by 48.33% to ¥54,845,685.02, reflecting strategic investments in pharmaceutical technology and an increase in R&D personnel[16] - Research and development expenses amounted to 54,845,685.02 CNY, up from 36,975,781.74 CNY, reflecting a significant increase of approximately 48.3% year-over-year[40] Government Support and Subsidies - The company received government subsidies amounting to ¥20,114,458.03 during the reporting period[9] Financial Management - The company reported a significant decrease in financial expenses by 185.46%, resulting in a negative amount of -¥8,621,600.07, mainly due to RMB to USD exchange rate fluctuations[16] - The financial expenses showed a significant improvement, with a net income of -8,621,600.07 CNY compared to 10,088,475.30 CNY in the previous year, indicating a positive change in financial management[40] Market Strategy - The company is focusing on expanding its market presence and enhancing its product offerings through increased investment in R&D and strategic initiatives[40]

Financial Performance - Net profit attributable to shareholders rose by 37.21% to CNY 104,230,871.71 for the current period[7] - Operating revenue grew by 29.86% to CNY 447,324,504.83 for the current period[7] - Basic earnings per share increased by 42.42% to CNY 0.47[7] - The net profit after deducting non-recurring gains and losses increased by 49.76% to CNY 101,239,522.40 for the current period[7] - Net profit attributable to the parent company was ¥260,898,703.74, reflecting a 30% increase from ¥200,765,764.29 in the previous year[16] - Net profit for the period was CNY 246,203,162.56, compared to CNY 216,865,622.76 in the previous period, reflecting an increase of approximately 13.5%[47] - The company’s total profit for the period was CNY 273,650,721.53, compared to CNY 261,715,908.05 in the previous period, representing an increase of about 4.0%[47] - The net profit for the quarter reached CNY 5,039,312.01, compared to CNY 2,641,574.48 in the same period last year, indicating a significant increase of approximately 90.5%[51] Revenue and Costs - Total operating revenue for the period reached CNY 1,204,962,585.97, an increase from CNY 895,938,102.03 in the previous period, representing a growth of approximately 34.4%[46] - Total operating costs amounted to CNY 955,352,003.10, up from CNY 684,142,364.61, indicating a rise of about 39.6%[46] - Total operating costs amounted to ¥354,961,388.42, up 37.5% from ¥258,148,730.95 in the prior period[37] Assets and Liabilities - Total assets increased by 11.28% to CNY 2,934,721,034.79 compared to the end of the previous year[7] - The total assets of the company reached 2,934.72 million RMB, an increase from 2,637.20 million RMB at the beginning of the period[32] - The total liabilities as of October 31, 2018, are 537.06 million RMB, up from 482.17 million RMB at the beginning of the period[32] - The company's total assets decreased to ¥1,419,338,527.44 from ¥1,444,943,970.32 at the beginning of the period, reflecting a decline of 1.8%[35] - Total liabilities decreased to ¥154,042,800.25 from ¥176,561,039.62, a reduction of 12.8%[36] Cash Flow - The net cash flow from operating activities decreased significantly by 87.46% to CNY 11,867,206.27[7] - Cash flow from operating activities amounted to CNY 273,080,500.76, up from CNY 246,192,999.32 year-over-year, representing an increase of about 10.9%[52] - The company’s cash flow from financing activities showed a net outflow of CNY -40,482,106.52, an improvement from CNY -55,397,382.00 in the previous year[54] - The net cash flow from investing activities was negative at CNY -762,387,980.92, compared to CNY -209,278,870.94 in the previous year, indicating a significant increase in cash outflow[54] Research and Development - Research and development expenses rose to ¥101,412,458.93, a 48% increase from ¥68,618,202.28, driven by the company's commitment to technology-driven growth[15] - Research and development expenses increased to ¥46,686,069.25, a rise of 57.5% compared to ¥29,621,198.72 in the previous period[37] - The company is focusing on enhancing its innovative drug R&D and production service system, which is expected to become a new growth point for performance[21] Shareholder Information - The company reported a total of 11,362 common shareholders at the end of the reporting period[11] - ASYMCHEM LABORATORIES, INCORPORATED held 41.69% of the shares, making it the largest shareholder[11] - The company did not engage in any repurchase transactions during the reporting period[12] Other Financial Metrics - The weighted average return on net assets was 5.02%, an increase of 0.97% compared to the previous year[7] - The company reported a significant increase in cash inflow from other operating activities, totaling CNY 36,300,531.09, compared to CNY 43,071,978.98 in the previous year, a decrease of about 16.5%[52] - The company reported an increase in other income to ¥4,413,787.50 from ¥10,873,550.90, indicating a decrease of 59.3%[39] - The company reported a total comprehensive income of CNY 250,752,408.40, up from CNY 216,212,209.76, which is an increase of about 15.9%[48]

Financial Performance - The company reported a revenue of RMB 1.5 billion for the first half of 2018, representing a year-on-year increase of 25%[1] - The company's revenue for the first half of 2018 was ¥757,638,081.14, representing a 37.38% increase compared to ¥551,472,667.93 in the same period last year[19] - The net profit attributable to shareholders was ¥156,667,832.03, up 25.53% from ¥124,802,707.56 year-on-year[19] - The net profit after deducting non-recurring gains and losses was ¥141,798,262.67, reflecting a significant increase of 54.83% compared to ¥91,583,545.03 in the previous year[19] - The net cash flow from operating activities reached ¥261,213,294.49, a 72.32% increase from ¥151,590,560.89 in the same period last year[19] - In the first half of 2018, the company achieved total revenue of 758 million RMB, a year-on-year increase of 37.38%[53] - The net profit attributable to shareholders was 157 million RMB, up 25.53% compared to the same period last year, while the net profit excluding non-recurring items reached 142 million RMB, reflecting a growth of 54.83%[53] Market Expansion and Strategy - The company has expanded its market presence in Europe, with a 20% increase in sales in that region compared to the previous year[1] - Future guidance estimates a revenue growth of 30% for the full year 2018, driven by new product launches and market expansion[1] - The company aims to expand its service offerings into clinical CRO business and large molecule biopharmaceuticals through strategic partnerships[27] - The company continues to deepen its focus on the innovative drug CDMO sector, leveraging its strong technical foundation and rich project experience to support steady growth in overseas business[103] - The domestic market expansion is a key growth driver, with the company enhancing its capabilities to provide comprehensive services for innovative drugs across the entire industry chain[103] - The company has implemented a dual-engine strategy to accelerate market expansion both domestically and internationally, with positive results gradually emerging[103] Research and Development - The company plans to invest RMB 200 million in R&D for new drug development in the next fiscal year, aiming to enhance its product pipeline[1] - R&D investment in the first half of 2018 was 70.57 million RMB, representing an increase of 80.95% year-on-year, emphasizing the company's commitment to technological innovation[63] - The company has a strong R&D team, with over 40% of its total workforce dedicated to research, and maintains a leading position in R&D investment within the industry[38] - The company has applied for a total of 155 patents, including 137 invention patents, demonstrating its commitment to innovation and technology advancement[39] - The company has developed capabilities in peptide synthesis, with a team of 30 people able to handle 5-8 peptide R&D/production projects simultaneously, covering preclinical to Phase II clinical projects[66] Operational Excellence - The company continues to focus on CDMO services, providing integrated solutions from drug development to commercialization, serving major pharmaceutical companies globally[27] - The company has established a comprehensive service system including CMC services for innovative drugs, MAH business, formulation R&D and production, and clinical trial services, creating a "one-stop service" ecosystem for drug development and production[44] - The company has successfully passed FDA inspections with zero defects in 2014 and has maintained compliance with international quality standards, enhancing its service capabilities[48] - The company has established a comprehensive cGMP standard quality system, successfully passing FDA inspections with zero defects in 2014 and subsequent years for multiple subsidiaries[110] Environmental Commitment - The company has achieved world-leading levels in green pharmaceutical technology development and commercialization, focusing on sustainable practices[30] - The company is actively pursuing green pharmaceutical technologies and aims to create a sustainable development model with low energy consumption and emissions[109] - The company has implemented a comprehensive environmental monitoring plan, including online monitoring of wastewater and annual external assessments of waste gas emissions[152][153] - Kailaiying Life Sciences was recognized as a national-level "green factory," emphasizing its commitment to environmentally friendly production methods[153] Risk Management - The company faces potential risks related to regulatory changes and market competition, which are detailed in the risk management section of the report[1] - The company faces risks related to the lifecycle changes of innovative drugs, including potential market competition from generics once patents expire[104] - There is a risk of not passing continuous reviews by international drug regulatory authorities, which could impact market access for products[105] - The company emphasizes the importance of maintaining a high level of R&D investment to sustain its technological leadership, despite the inherent risks and uncertainties[106] Shareholder Returns and Corporate Governance - The company will not distribute cash dividends for the current fiscal year, opting to reinvest profits into growth initiatives[1] - The company plans to distribute profits through cash dividends, stock, or a combination of both, ensuring that cash dividends are prioritized[121] - The company commits to distributing no less than 10% of the annual distributable profits as cash dividends[121] - The company has established a mechanism to ensure the continuity and stability of its dividend distribution policy[121] - The company will ensure that any changes to the shareholder return plan do not violate established principles[121] Employee Engagement and Talent Development - The company has actively recruited 21 senior talents in the first half of 2018, including 10 PhDs, to enhance its core competitiveness[75] - The company has established various talent incentive mechanisms to retain core technical personnel, crucial for maintaining its competitive edge[107] - The company is focused on expanding its talent pool, with nearly 70% of its workforce holding a bachelor's degree or higher, ensuring a strong foundation for sustainable development[47]

凯莱英医药集团（天津）股份有限公司 2018 年第一季度报告正文 证券代码：002821 证券简称：凯莱英 公告编号：2018-024 凯莱英医药集团（天津）股份有限公司 2018 年第一季度报告正文 凯莱英医药集团（天津）股份有限公司 2018 年第一季度报告正文 第一节 重要提示 1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人 HAO HONG、主管会计工作负责人杨蕊及会计机构负责人(会 计主管人员)李来明声明：保证季度报告中财务报表的真实、准确、完整。 2 凯莱英医药集团（天津）股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 363,656,523.27 | 290,097,601.30 | 25. ...

Financial Performance - The company's operating revenue for 2017 was approximately ¥1.42 billion, representing a year-over-year increase of 28.99% compared to ¥1.10 billion in 2016[18]. - The net profit attributable to shareholders for 2017 was approximately ¥341.29 million, a 35.04% increase from ¥252.74 million in 2016[18]. - The net profit after deducting non-recurring gains and losses was approximately ¥296.86 million, reflecting a 20.58% increase from ¥246.20 million in 2016[18]. - The basic earnings per share for 2017 was ¥1.51, up 9.42% from ¥1.38 in 2016[18]. - The total assets at the end of 2017 were approximately ¥2.64 billion, a 7.87% increase from ¥2.44 billion at the end of 2016[18]. - The net assets attributable to shareholders at the end of 2017 were approximately ¥2.06 billion, an increase of 17.29% from ¥1.75 billion at the end of 2016[18]. - The company reported a net cash flow from operating activities of approximately ¥196.40 million, a decrease of 29.44% compared to ¥278.36 million in 2016[18]. - The company received government subsidies amounting to approximately ¥57.98 million in 2017, significantly higher than ¥10.24 million in 2016[23]. - The company experienced a decline in the weighted average return on equity, which was 17.93% in 2017, down from 24.11% in 2016[18]. - The company reported a total of four quarterly revenues, with the fourth quarter reaching approximately ¥527.10 million, the highest among the quarters[22]. Market Position and Strategy - The company is a leading CDMO in China, focusing on global pharmaceutical process innovation and commercialization, providing one-stop CMC services to large and medium-sized pharmaceutical and biotechnology companies[5]. - The company has established partnerships with major multinational pharmaceutical companies, enhancing its market position and service capabilities[5]. - The company is focused on expanding its market presence and exploring potential mergers and acquisitions to enhance its service offerings[5]. - The company aims to accelerate domestic market expansion while continuing to develop its existing CDMO business, enhancing its service ecosystem[32]. - The company is strategically positioning itself in the large molecule biopharmaceutical sector, leveraging existing bioproduction technology and collaborating with top domestic research institutions to accelerate development in this area[104]. - The company plans to leverage favorable domestic policies to expand its full-chain service system for new drug R&D[102]. - The company is committed to building a "one-stop service ecosystem" for domestic and international pharmaceutical enterprises[99]. Research and Development - The company holds 122 patents, including 54 granted invention patents in China, showcasing its strong R&D capabilities and technological leadership[35]. - The company is actively exploring new technologies such as photochemistry and electrochemistry for future applications in commercial production[36]. - The company’s technology-driven strategy has led to a steady increase in the number of technology development projects undertaken[43]. - R&D investment accounted for 6.83% of total revenue, nearing 100 million yuan, ensuring continuous output of technological value and building industry barriers[51]. - The company introduced 38 senior talents in 2017, including 14 PhDs and 10 foreign experts, enhancing its R&D and management capabilities[60]. - The company completed the construction of its R&D center and initiated trial production at its drug production project, enhancing its overall R&D capabilities[59]. Risk Management - The company faces several risks, including the potential delisting or large-scale recall of major innovative drugs, operational risks of clinical projects, and risks related to international trade friction and exchange rate fluctuations[5]. - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements related to future plans and development strategies[5]. Environmental Responsibility - The company is recognized as a "Green Factory" by the Ministry of Industry and Information Technology, highlighting its commitment to green manufacturing[50]. - The company has implemented green pharmaceutical technologies, significantly reducing waste emissions and energy consumption, aligning chemical production with environmental harmony[169]. - The company has a total of 112,863,500 shares before the stock incentive plan, which increased to 115,055,353 shares after the plan was implemented[179]. - The company has established a dedicated hazardous waste storage area that complies with national requirements[171]. - The company conducted two emergency response drills for environmental incidents in 2017, improving its emergency measures[172]. Shareholder Returns - The company plans to distribute cash dividends of no less than 10% of the distributable profits each year, ensuring a stable return to shareholders[122]. - The proposed cash dividend for 2017 is RMB 3.50 per 10 shares, with a total cash dividend amounting to RMB 80,535,947.10, which is 100% of the distributable profit[113]. - The company has maintained a consistent cash dividend policy over the past three years, with cash dividends of RMB 30,709,004.71 in 2015 and RMB 57,525,676.50 in 2016[112]. - The company reported a commitment to comply with regulations regarding share reduction, ensuring that any reduction price will not be lower than 110% of the issue price[120]. Corporate Governance - The financial report confirms the accuracy and completeness of the financial statements, with the board of directors and management taking legal responsibility for the report[4]. - The company has not reported any non-standard audit opinions for the reporting period, indicating a clean audit[129]. - The company has committed to fulfilling all public commitments made during its initial public offering, ensuring investor protection[125]. - The company has a plan to minimize investor losses in case of any unfulfilled commitments, demonstrating a proactive approach to investor relations[125]. Operational Highlights - The company established a comprehensive service system including innovative drug CMC services, MAH business, formulation development, and clinical trial services, contributing to its market expansion[32]. - The company successfully passed FDA inspections for three subsidiaries with "zero defects," enhancing its international quality system alignment[40]. - The company secured 65 project orders from over 40 domestic pharmaceutical companies during the reporting period, indicating significant growth in domestic business[45]. - The company achieved steady growth in performance, driven by its deepening global innovative drug CDMO business and expanding project collaborations with major pharmaceutical giants[49].

Financial Performance - Operating revenue for the current period was CNY 344,465,434.10, reflecting a 9.24% increase year-on-year[7] - Net profit attributable to shareholders decreased by 23.74% to CNY 75,963,056.73 compared to the same period last year[7] - Basic earnings per share fell by 40.00% to CNY 0.33[7] - Net cash flow from operating activities decreased by 39.05% to CNY 94,602,438.43[7] - The company's net profit for Q3 2017 was CNY 77,195,530.92, a decrease of 30.5% from CNY 110,938,171.81 in the previous year[49] - The company reported a revenue increase of 15% year-over-year for Q3 2017, reaching approximately 1.5 billion RMB[27] - The company reported a significant increase in management expenses, which rose to CNY 65,503,851.76 from CNY 47,742,059.62, reflecting higher operational costs[49] Assets and Liabilities - Total assets increased by 2.05% to CNY 2,495,068,905.20 compared to the end of the previous year[7] - The total liabilities amounted to CNY 483,006,788.35, down from CNY 611,905,190.55, showing a reduction in financial obligations[43] - Cash and cash equivalents decreased significantly to CNY 138,523,316.99 from CNY 517,101,827.26, indicating a liquidity challenge[44] - Accounts receivable decreased to CNY 240.57 million from CNY 294.94 million, indicating improved cash flow management[40] - Inventory increased to CNY 263.43 million from CNY 218.75 million, reflecting the company's strategy to support future sales growth[40] Shareholder Information - Net assets attributable to shareholders rose by 9.29% to CNY 1,917,306,815.53 year-on-year[7] - The total number of shareholders at the end of the reporting period was 14,701[11] - ASYMCHEM LABORATORIES, INCORPORATED held 41.83% of the shares, making it the largest shareholder[11] Investments and Projects - The company plans to invest a total of 600 million RMB in a green pharmaceutical technology industrialization project in Dunhua City, covering an area of about 165,000 square meters, with an initial investment of 250 million RMB[19] - The company has made significant progress in expanding its project reserves in innovative drug CMC services and MAH business, which is expected to support future revenue growth[16] - Fixed assets rose by 47.19% to RMB 723,655,952.48, driven by investments in infrastructure and R&D equipment to enhance the domestic new drug R&D service system[15] Stock Price Stabilization Measures - The company plans to stabilize its stock price by implementing a buyback program, with a total amount not exceeding 50% of the previous fiscal year's audited net profit attributable to the parent company[23] - The company will actively take measures to stabilize its stock price within 5 trading days after the shareholders' meeting approves the specific plan[23] - The company has committed to maintaining compliance with listing conditions while implementing stock price stabilization measures[23] - The company will publicly explain any failure to implement stock price stabilization measures and apologize to shareholders and the public[23] - The company will ensure that the shareholding structure remains compliant with listing requirements after implementing stock price stabilization measures[23] Future Outlook - The company provided a future outlook, projecting a revenue growth of 10-15% for the next quarter, driven by new product launches[27] - The company aims to introduce three new products in the next quarter, which are anticipated to contribute an additional 5% to overall revenue[27] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2018[27] Research and Development - Investment in R&D increased by 25% compared to the previous year, focusing on innovative drug development[27] - The company has significantly increased its R&D efforts in 2017, particularly in the second half, to enhance new technology and process development, establishing a comprehensive service system for domestic pharmaceutical companies[33] Compliance and Commitments - The company will strictly fulfill all public commitments made during its initial public offering and actively accept social supervision[29] - The company will publicly explain the specific reasons for any failure to fulfill commitments and apologize to shareholders and the public[30] - The company will bear legal liability for any losses caused to investors due to unfulfilled commitments[30]